Tango Therapeutics, Inc. (TNGX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low14.5·High14.5
P/B Ratio
↑
7.93
↑+208% vs avg
5yr avg: 2.58
30Y Low1.7·High25.9
ROE
↓
-37.2%
↓+8% vs avg
5yr avg: -40.4%
30Y Low-224%·High-30%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TNGX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tango Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.2B | $1.0B | $338M | $936M | $637M | $679M | $1.0B | — |
| Enterprise Value | $3.1B | $951M | $304M | $909M | $618M | $538M | $980M | — |
| P/E Ratio → | -27.15 | — | — | — | — | — | — | — |
| P/S Ratio | 51.47 | 16.50 | 8.02 | 25.63 | 25.61 | 18.34 | 130.71 | — |
| P/B Ratio | 7.93 | 2.97 | 1.69 | 3.70 | 2.55 | 1.97 | 25.92 | — |
| P/FCF | — | — | — | — | — | — | 14.51 | — |
| P/OCF | — | — | — | — | — | — | 14.28 | — |
P/E links to full P/E history page with 30-year chart
TNGX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.24 | 7.24 | 24.88 | 24.85 | 14.53 | 128.03 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | 14.21 | — |
TNGX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Tango Therapeutics, Inc. earns an operating margin of -178.4%. Operating margins have expanded from -312.6% to -178.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -37.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.3% | 96.3% | 100.0% | 100.0% | 100.0% | 100.0% | 78.8% | -30.9% |
| Operating Margin | -178.4% | -178.4% | -346.1% | -312.6% | -446.8% | -157.1% | -681.8% | -61.5% |
| Net Profit Margin | -162.9% | -162.9% | -309.7% | -278.5% | -435.1% | -157.2% | -678.8% | -57.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -37.2% | -37.2% | -57.6% | -40.5% | -36.4% | -30.4% | -223.5% | -178.3% |
| ROA | -28.4% | -28.4% | -36.2% | -24.3% | -23.1% | -16.5% | -39.5% | -25.3% |
| ROIC | -38.5% | -38.5% | -55.7% | -37.5% | -38.4% | -39.4% | -671.6% | — |
| ROCE | -34.0% | -34.0% | -45.9% | -31.0% | -26.4% | -18.6% | -53.2% | -50.7% |
TNGX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $112M exceeds total debt of $34M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | 0.18 | 0.15 | 0.16 | 0.00 | 0.20 | 1.08 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.23 | -0.17 | -0.11 | -0.08 | -0.41 | -0.53 | -1.82 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | -0.30 | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($112M) exceeds total debt ($34M)
TNGX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Tango Therapeutics, Inc.'s current ratio of 16.32x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.54x to 16.32x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 16.32 | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 4.73 | 1.61 |
| Quick Ratio | 16.32 | 16.32 | 6.98 | 7.54 | 6.76 | 12.10 | 4.73 | 1.61 |
| Cash Ratio | 15.83 | 15.83 | 6.76 | 7.33 | 6.59 | 11.93 | 4.65 | 1.56 |
| Asset Turnover | — | 0.16 | 0.13 | 0.09 | 0.06 | 0.07 | 0.04 | 0.44 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 29.36 | 19.71 | 95.35 | — |
TNGX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tango Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | 6.9% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $116M | $109M | $95M | $88M | $62M | $87M | $87M |
Peer Comparison
Compare TNGX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TNGXYou | $3B | -27.1 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 RVMD | $32B | -25.4 | — | — | — | — | -58.1% | -54.3% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 AUPH | $2B | 7.8 | 20.4 | 15.9 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 PMVP | $77M | -1.3 | — | — | — | — | -29.2% | -38.0% | — |
 ARQT | $3B | -185.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 NUVL | $7B | -26.5 | — | — | — | — | -29.5% | -32.6% | — |
 TYRA | $2B | -16.8 | — | — | — | — | -39.8% | -44.8% | — |
 AZN | $287B | 28.3 | 16.0 | 24.4 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See TNGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNGX vs RVMD
Side-by-side business, growth, and profitability comparison vs Revolution Medicines, Inc..
Start ComparisonTNGX — Frequently Asked Questions
Quick answers to the most common questions about buying TNGX stock.
What is Tango Therapeutics, Inc.'s P/E ratio?
Tango Therapeutics, Inc.'s current P/E ratio is -27.1x. This places it at the 50th percentile of its historical range.
What is Tango Therapeutics, Inc.'s ROE?
Tango Therapeutics, Inc.'s return on equity (ROE) is -37.2%. The historical average is -86.3%.
Is TNGX stock overvalued?
Based on historical data, Tango Therapeutics, Inc. is trading at a P/E of -27.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Tango Therapeutics, Inc.'s profit margins?
Tango Therapeutics, Inc. has 96.3% gross margin and -178.4% operating margin.